drugset / Trial / NCT02879578
Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase 2, open-label, fixed-dose titration study to evaluate the safety and tolerability of NBI-98854 administered once daily for a total of 24 weeks in children, adolescents, and adults with Tourette Syndrome (TS).
Timeline
- Start
- 2016-07-25
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valbenazine | Small molecule | 10 mg | — |
| Subject | Valbenazine | Small molecule | 20 mg | — |
| Subject | Valbenazine | Small molecule | 40 mg | — |
| Subject | Valbenazine | Small molecule | 80 mg | — |